Evidence map›Paper›PMID 39353532›Full record

ArticleJournal of advanced research2025

Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy.

Guiqin Huang, Yawen Cai, Menghui Ren, Xiaoyu Zhang, Yu Fu, Run Cheng, Yingdi Wang, Mingxing Miao, Lingpeng Zhu, Tianhua Yan

Abstract read
In one paragraph

Article in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. PRRC2A-mediated mCell death & disease · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guiqin HuangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Yawen CaiSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Menghui RenSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Xiaoyu ZhangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Yu FuSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Run ChengSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Yingdi WangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China.
Mingxing MiaoNational Experimental Teaching Demonstration Center of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China. Electronic address: mmx0224@cpu.edu.cn.
Lingpeng ZhuThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu 214023, China. Electronic address: zhulingpeng@njmu.edu.cn.
Tianhua YanSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China. Electronic address: 1020050806@cpu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTriple-negative breast cancer (TNBC) is the primary cause of breast cancer-induced death in women. Literature has confirmed the benefits of Salidroside (Sal) in treating TNBC. However, the study about potential therapeutic targets and mechanisms of Sal-anchored TNBC remains limited.

objectiveThis study was designed to explore the main targets and potential mechanisms of Sal against TNBC.

methodsNetwork pharmacology, bioinformatics, and machine learning algorithm strategies were integrated to examine the role, potential targets, and mechanisms of the Sal act in TNBC. MDA-MB-231 cells and tumor-bearing nude mice were chosen for in vitro and in vivo experimentation. Cell viability and cytotoxicity were determined using CCK-8, LDH test, and Calcein-AM/PI staining. Antioxidant defense, lipid peroxidation, and iron metabolism were explored using glutathione, glutathione peroxidase, malondialdehyde (MDA), C11-BODIPY 581/591 probe, and FerroOrange dye. Glutathione peroxidase 4 (GPX4) or stearoyl-CoA desaturase 1 (SCD1) overexpression or nuclear receptor co-activator 4 (NCOA4) deficiency was performed to demonstrate the mechanism of Sal on TNBC.

resultsThe prediction results confirmed that 22 ferroptosis-related genes were identified in Sal and TNBC, revealing that the potential mechanism of the Sal act on TNBC was linked with ferroptosis. Besides, these genes were mainly involved in the mTOR, PI3K/AKT, and autophagy signaling pathway by functional enrichment analysis. The in vitro validation results confirmed that Sal inhibited TNBC cell proliferation by modulating ferroptosis via elevation of intracellular Fe

conclusionsOverall, this study elucidates TNBC pathogenesis closely linked to ferroptosis and identifies potential biomarkers in TNBC. Meanwhile, the study elucidates that Sal sensitizes TNBC to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy, regulated by PI3K/AKT/mTOR signaling pathways. Our findings provide a theoretical basis for applying Sal to treat TNBC.

Indexed as

FerritinsFerroptosisGlucosidesLipogenesisNuclear Receptor CoactivatorsPhenolsStearoyl-CoA DesaturaseTriple Negative Breast NeoplasmsAnimalsAutophagyCell Line, TumorFemaleHumansMiceMice, NudeSignal TransductionFerritinsGlucosidesNCOA4 protein, humanNuclear Receptor CoactivatorsPhenolsrhodiolosideStearoyl-CoA DesaturaseFerroptosismTORNCOA4-mediated ferritinophagySalidrosideSCD1-mediated lipogenesisTriple-negative breast cancer

Identifiers

PMID39353532
PMCPMC12302663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.